Research Link- Relationship Between Disease-Modifying Therapy and Depression in MS

Relationship Between Disease-Modifying Therapy and Depression in MS

“Many prescribers of disease-modifying therapies for multiple sclerosis believe that interferon beta (IFNB) is more likely that glatiramer acetate (GA) to increase depression during the course of MS treatment.  Therefore, newly diagnosed patients with a history of depression are often placed on GA therapy from the onset of MS treatment.  The aim of this study was to examine the relationship between disease-modifying therapy type and depression among patients with relapsing-remitting MS. Patients with RRMS who remained on a single course of therapy (either IFNB or GA) were asked to complete the Beck Depression Inventory at treatment initiation and every 6 months thereafter for up to 4 years. Neither interferon beta nor glatiramer acetate appeared to exacerbate depressive symptoms in patients with relapsing-remitting MS who remain on their initial therapy”

For the original study by Kirzinger et al : click here


BC PharmaCare Drug Review

BC PharmaCare is currently undergoing a drug review process of alemtuzumab (LEMTRADA™) and would like your input!!

Deadline is Friday, July 11th. (You don’t need to have tried the drug)

If you are a patient with MS please follow this link
If you are a caregiver please follow this link

Below is the BCPharmacare Drug Information sheet on Lemtrada (alemtuzumab)


Research Link- MS Progression Linked to Atrophy of Grey Matter

A study by Cecilie Jacobsen et. al was recently published on the atrophy of grey and white matter in persons with MS over a 10 year period.  Their study goals were to find MRI biomarkers associated with long-term progression of disability in persons with MS.  Their results showed that grey matter atrophy seen on MRI is more closely linked to MS progression than white matter atrophy.  81 individuals with MS were involved in the 10 year follow-up study.  Investigators calculated percentage volume change of white and grey matter between different time points to determine changes in global and tissue-specific atrophy.  Increase in the Expanded Disability Status Scale of ≥1.0 from baseline to 5-year and 10-year follow-up determined disability progression.

Overall, grey matter atrophy showed better association with disease progression than white matter atrophy over 5-year and 10-year follow-up. The study authors say “assessment of grey matter pathology may add to the understanding of the disease progression in MS” and help overcome the clinical-MRI paradox of MRI not being well known to correlate very well with clinical outcomes.

To read Dr. Laurie Barclay’s article on the study click here.

Original study is published in Journal of Neurology, Neurosurgery and Psychiatry

brain atrophy

The MRI image above shows atrophy from a different study on relapsing remitting MS.

MS in Focus: Information, Technology and MS

Whether a person is newly-diagnosed or has had MS for a long time, information in today’s multi-media world can be overwhelming, and many people with MS may be unsure of where even to begin looking for the information they need. While the Internet can offer a mass of information about MS, it can also be a source of inaccurate, biased, deceiving or confusing information. The key is having the resources to be able to filter trustworthy content from the rest. This MS in focus provides guidance to help people with MS and health care professionals use the Internet to its fullest potential.